Lintuzumab: differenze tra le versioni
Vai alla navigazione
Vai alla ricerca
Contenuto cancellato Contenuto aggiunto
ins. testo tradotto da en.wiki |
→Note: ins. bibl. |
||
| Riga 41: | Riga 41: | ||
== Note == |
== Note == |
||
<references/> |
<references/> |
||
== Bibliografia == |
|||
* {{cite book|author=Frank Ashall|title=Le grandi scoperte scientifiche|url=http://books.google.com/books?id=GXsecqAh6MEC&pg=PA245|accessdate=|year=1999|publisher=Armando Editore|isbn=9788871449494|pages=245–}} |
|||
* {{cite book|author1=Abul K. Abbas|author2=Andrew H. Lichtman|author3=Shiv Pillai|title=Immunologia cellulare e molecolare|url=http://books.google.com/books?id=9SFm3nMO_gUC&pg=PA79|accessdate= |year=2010|publisher=Elsevier srl|isbn=9788821431760|pages=79–}} |
|||
* {{cite book|author1=Abul K. Abbas|author2=Andrew H. Lichtman|title=Le basi dell'immunologia|url=http://books.google.com/books?id=szHkdI9buskC&pg=PA70|accessdate|year=2006|publisher=Elsevier srl|isbn=9788885675858|pages=70–}} |
|||
* {{cite book|author1=Humphrey P. Rang|author2=M. Maureen Dale|author3=James M. Ritter|title=Farmacologia|url=http://books.google.com/books?id=HGcP_ip4SmgC&pg=PA778|accessdate|year=2008|publisher=Elsevier srl|isbn=9788821430237|pages=778–}} |
|||
* {{cite book|author=Enzo Fagiolo|title=Immunoematologia|url=http://books.google.com/books?id=ErRtMU7SKhkC&pg=PA16|accessdate=|year=2007|publisher=Mediserve s.r.l.|isbn=9788882041359|pages=16–}} |
|||
* {{cite book|author=Paolo Larizza|title=Trattato di medicina interna|url=http://books.google.com/books?id=Rt4_C55_Ls4C&pg=PA909|accessdate=|year=2005|publisher=PICCIN|isbn=9788829917211|pages=909–}} |
|||
* {{cite book|author=Angelo Sghirlanzoni|title=Terapia Delle Malattie Neurologiche|url=http://books.google.com/books?id=LCNUGXlL4FQC&pg=PA113|accessdate= |date=3 April 2010|publisher=Springer|isbn=9788847011199|pages=113–}} |
|||
* {{cite book|author=Thomas C. King|title=Patologia|url=http://books.google.com/books?id=1CgV-Td_I3oC&pg=PA156|accessdate= |year=2008|publisher=Elsevier srl|isbn=9788821430190|pages=156–}} |
|||
* {{cite web | url = http://whqlibdoc.who.int/druginfo/INN_2000_list43.pdf WHO-Lista INN degli Anticorpi monoclonali| title = whqlibdoc.who.int | author = | authorlink = | coauthors = | date =|format = | work = | publisher = | pages = | language = en | archiveurl = | archivedate = | quote =| accessdate = }} |
|||
* {{en}}{{cite book|author=Marie A. Simmons|title=Monoclonal antibodies: new research|url=http://books.google.com/books?id=jxhKskARw6IC|accessdate=|year=2005|publisher=Nova Publishers|isbn=9781594542473}} |
|||
* {{en}}{{cite book|author=Zhiqiang An|title=Therapeutic Monoclonal Antibodies: From Bench to Clinic|url=http://books.google.com/books?id=agdx2rtK7E0C|accessdate= |date=8 September 2009|publisher=John Wiley and Sons|isbn=9780470117910}} |
|||
* {{en}}{{cite book|author=James W. Goding|title=Monoclonal antibodies: principles and practice : production and application of monoclonal antibodies in cell biology, biochemistry and immunology|url=http://books.google.com/books?id=jPk4ZY4CnQQC|accessdate=|year=1996|publisher=Academic Press|isbn=9780122870231}} |
|||
* {{en}}{{cite book|author=Steve Shire|title=Current Trends in Monoclonal Antibody Development and Manufacturing|url=http://books.google.com/books?id=YTbJpdPhgT4C|accessdate= |date=April 2009|publisher=Springer|isbn=9780387766423}} |
|||
=== Lintuzumab === |
|||
* {{en}}{{cite book|author=Raymond M. Reilly|title=Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer|url=http://books.google.com/books?id=Y4ZU1LuqeAoC&pg=PA233|accessdate= |date=2 August 2010|publisher=John Wiley and Sons|isbn=9780470243725|pages=233–}} |
|||
* {{en}}{{cite book|author1=Razelle Kurzrock|author2=Maurie Markman|title=Targeted Cancer Therapy|url=http://books.google.com/books?id=VqMRxhXUMNwC&pg=PA25|accessdate= |date=7 April 2008|publisher=Humana Press|isbn=9781603274234|pages=25–}} |
|||
* {{en}}{{cite book|author=Judith E. Karp|title=Acute myelogenous leukemia|url=http://books.google.com/books?id=l0XWHNYyxBYC&pg=PA241|accessdate= |year=2007|publisher=Humana Press|isbn=9781588296214|pages=241–}} |
|||
* {{en}}{{cite book|author1=Hagop Kantarjian|author2=Stefan Faderl|title=Leukemias: Principles and Practice of Therapy|url=http://books.google.com/books?id=y0y_kP7PLYcC&pg=PA143|accessdate= |date=1 January 2010|publisher=John Wiley and Sons|isbn=9781405182355|pages=143–}} |
|||
* {{de}}{{cite book|author1=Christoph Huber|author2=Hans-Georg Rammensee|author3=Thomas Wölfel|coauthors=Cedrik Britten|title=Krebsimmuntherapien: Standards und Innovationen|url=http://books.google.com/books?id=ZEj76h7GI1UC&pg=PA80|accessdat |year=2008|publisher=Deutscher Ärzteverlag|isbn=9783769112122|pages=80–}} |
|||
{{Portale|medicina}} |
{{Portale|medicina}} |
||
Versione delle 13:26, 27 mar 2011
Template:Disclaimer medico Template:Farmaco Il lintuzumab o SGN-33 è un anticorpo monoclonale umanizzato utilizzato nel trattamento di forme tumorali. Il farmaco è stato sviluppato da Seattle Genetics[1] per il trattamento della leucemia mieloide acuta (AML), una condizione che provoca la morte di 9.000 persone l'anno negli Stati Uniti. Lintuzumab è attiva sulla proteina CD33 , che si sovraesprime nella ALM e in altre malattie mieloproliferative, mentre non appare molto presente nelle cellule normali.
Le ricerche sulla AML e il lintuzumab sono stati abbandonate nel 2010 quando un trial di fase IIb non è riuscito a mostrare un aumento della sopravvivenza.[2]
A partire dal 2010, Seattle Genetics conduce studi clinici di Fase II sul lintuzumab in associazione con bortezomib come trattamento delle sindromi mielodisplastiche.
Note
- ^ (EN) Seattle Genetics, su seagen.com.
- ^ (EN) Seattle Genetics Stops Trial of Lintuzumab, a Leukemia Drug - NYTimes.com, su prescriptions.blogs.nytimes.com.
Bibliografia
- Frank Ashall, Le grandi scoperte scientifiche, Armando Editore, 1999, pp. 245–, ISBN 9788871449494.
- Immunologia cellulare e molecolare, Elsevier srl, 2010, pp. 79–, ISBN 9788821431760.
- Le basi dell'immunologia, Elsevier srl, 2006, pp. 70–, ISBN 9788885675858.
- Farmacologia, Elsevier srl, 2008, pp. 778–, ISBN 9788821430237.
- Enzo Fagiolo, Immunoematologia, Mediserve s.r.l., 2007, pp. 16–, ISBN 9788882041359.
- Paolo Larizza, Trattato di medicina interna, PICCIN, 2005, pp. 909–, ISBN 9788829917211.
- Angelo Sghirlanzoni, Terapia Delle Malattie Neurologiche, Springer, 3 April 2010, pp. 113–, ISBN 9788847011199.
- Thomas C. King, Patologia, Elsevier srl, 2008, pp. 156–, ISBN 9788821430190.
- (EN) WHO-Lista INN degli Anticorpi monoclonali whqlibdoc.who.int.
- (EN) Marie A. Simmons, Monoclonal antibodies: new research, Nova Publishers, 2005, ISBN 9781594542473.
- (EN) Zhiqiang An, Therapeutic Monoclonal Antibodies: From Bench to Clinic, John Wiley and Sons, 8 September 2009, ISBN 9780470117910.
- (EN) James W. Goding, Monoclonal antibodies: principles and practice : production and application of monoclonal antibodies in cell biology, biochemistry and immunology, Academic Press, 1996, ISBN 9780122870231.
- (EN) Steve Shire, Current Trends in Monoclonal Antibody Development and Manufacturing, Springer, April 2009, ISBN 9780387766423.
Lintuzumab
- (EN) Raymond M. Reilly, Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer, John Wiley and Sons, 2 August 2010, pp. 233–, ISBN 9780470243725.
- (EN) Targeted Cancer Therapy, Humana Press, 7 April 2008, pp. 25–, ISBN 9781603274234.
- (EN) Judith E. Karp, Acute myelogenous leukemia, Humana Press, 2007, pp. 241–, ISBN 9781588296214.
- (EN) Leukemias: Principles and Practice of Therapy, John Wiley and Sons, 1º January 2010, pp. 143–, ISBN 9781405182355.
- (DE) Cedrik Britten, Krebsimmuntherapien: Standards und Innovationen, Deutscher Ärzteverlag, 2008, pp. 80–, ISBN 9783769112122.